Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM study of abiraterone exposure and early biomarkers in metastatic castration-resistant prostate cancer
2014-004513-90Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa), sponsored by Radboud University Medical Center. Primary endpoint: Relation between abiraterone exposure and treatment response. Started Jan 2015; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-004513-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004513-90.